Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

San Diego, Calif., October 31, 2017 – Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics. Read more

Synthetic Genomics and Ceva Enter Agreement to Develop, Commercialize Next-Generation Vaccines for Animal Health

SAN DIEGO – October 31, 2017 – Synthetic Genomics, Inc. announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics’ next-generation synthetic RNA replicon platform to develop vaccines for livestock. The technology opens the door to more effective vaccines and therapeutics. Read more

Synthetic Genomics Partners with Duke Human Vaccine Institute on DARPA Pandemic Prevention Platform Program

October 26, 2017 — Synthetic Genomics, Inc. is part of the recently funded DARPA Pandemic Prevention Platform (P3) program aimed at establishing a system capable of halting viral pandemics within 60 days. As part of the collaboration, led by Duke, Synthetic Genomics will contribute synthetic biology technologies to enable rapid delivery of anti-viral countermeasures. Read more

BioXp™ Genomic Workstation Makes European Debut at VIB Research Institute in Belgium

SGI-DNA’s benchtop automated DNA printer to accelerate genomic research as part of VIB’s Technology Watch Initiative

FLANDERS, BELGIUM AND SAN DIEGO, Aug. 22, 2017 – SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, and VIB, a Belgian life science research institute, today announced that VIB will become the first institute in Europe to integrate the BioXp™ 3200 System in its workflows as part of its vision for adopting breakthrough technologies.  The BioXp™ 3200 System is the world’s first benchtop automated genomic workstation that rapidly prints high-quality, double-stranded DNA fragments and clones into any vector in an overnight run. With the BioXp™ 3200 System, VIB will be accelerating turnaround time for generating custom DNA for genomic research.

VIB’s Technology Watch Initiative implements new, emerging, and disruptive technologies into its laboratories and research facilities. Active since 2008, the Technology Watch program evaluates strategic technology investment opportunities and provides the funding to secure prototype instruments and early-stage technologies from high-potential fields such as Synthetic Biology, CRISPR, and single-cell analysis. The BioXp™ 3200 System will be placed in the lab of Thomas Jacobs, Ph.D., a VIB scientist in the VIB-UGent Center for Plant Systems Biology,  who is developing and optimizing plant genome editing through the use of CRISPR/Cas systems.

“The BioXp™ 3200 System will fundamentally change the way our research group approaches cloning. Not only will it greatly reduce our turnaround time for cloning projects, but also will hopefully open up new ways to test the gene editing systems we are developing,” says Dr. Jacobs.

“By automating rapid DNA synthesis, this will put VIB in a competitive position, allowing researchers to focus their time on the crucial scientific questions rather than on routine lab work,” adds Halina Novak, Ph.D., Technology Watch program manager at VIB.

Scientists are able to specifically design and clone genes with the BioXp™ System to answer key questions in their function  in biological systems. With the BioXp™ 3200 System, researchers do not need a template to obtain a gene of interest. Genes are built in silico, designed with sequence modifications to address the specific research.

“Automating gene synthesis promotes scientific discovery and advancement,” says Nathan Wood, president of SGI-DNA. “The global expansion of the BioXp™ 3200 System, notably to one of Europe’s most innovative research institutes, will help to facilitate further genomic breakthroughs in life science research.”

More information is available at sgidna.com/bxp3200.

About VIB

Basic research in life sciences is VIB’s raison d’être. VIB is pushing the boundaries of molecular mechanisms and how they rule living organisms, such as human beings, animals, plants and microorganisms, while also creating tangible results for the benefit of society. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University – and supported by a solid funding program, VIB unites the expertise of 75 research groups in a single institute. VIB’s technology transfer activities translate research results into new economic ventures which, in time, lead to new products that can be used in medicine, agriculture and other applications. VIB also engages actively in the public debate on biotechnology by developing and disseminating a wide range of science-based information about all aspects of biotechnology. More information: www.vib.be.

VIB Tech Watch

Through the strategic application of VIB Tech Watch funds, VIB labs boast groundbreaking new technologies such as those enabling human genome sequencing, bioinformatics, next generation DNA sequencing, and a diverse range of visualization and proteomics technologies. Over the years, Tech Watch has gathered in-depth information about disruptive technologies that could aid VIB scientists, sharing over 100 of these innovations with the entire organization in the last eight years and assisting researchers in obtaining funds to use these technologies to boost research output. VIB’s partnership with SGI-DNA is only one illustration of how the VIB Technology Watch team drives cutting-edge science.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines such as Vmax™ a novel, fast growing host system for molecular biology. To further enable synthetic biology workflows, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double stranded DNA fragments, automated cloning, as well as Next Generation Sequencing DNA library preparation. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology. More information is available at sgidna.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in energy, health care and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at syntheticgenomics.com.

###

Synthetic Genomics Contact:

Corporate Communications and Media
Ian Stone, Canale Communications
ian@canalecomm.com
619-849-6005

SGI-DNA Contact:

Liz Liner, Synthetic Genomics
pr@sgidna.com
858.433.2213

VIB Contact:

Halina Novak, VIB Tech Watch
halina.novak@vib.be
+32 9 244 66 11

ExxonMobil and Synthetic Genomics Report Breakthrough in Algae Biofuel Research

  • Algae strain developed and modified by Synthetic Genomics more than doubled oil production
  • Additional research and testing required before commercial application
  • Results published in peer-reviewed journal Nature Biotechnology

IRVING, Texas and LA JOLLA, Calif. – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an algae strain that more than doubled its oil content without significantly inhibiting the strain’s growth.

Using advanced cell engineering technologies at Synthetic Genomics, the ExxonMobil-Synthetic Genomics research team modified an algae strain to enhance the algae’s oil content from 20 percent to more than 40 percent. Results of the research were published today in the peer-reviewed journal Nature Biotechnology by lead authors Imad Ajjawi and Eric Moellering of Synthetic Genomics.

Researchers at Synthetic Genomics’ laboratory in La Jolla discovered a new process for increasing oil production by identifying a genetic switch that could be fine-tuned to regulate the conversion of carbon to oil in the algae species, Nannochloropsis gaditana. The team established a proof-of-concept approach that resulted in the algae doubling its lipid fraction of cellular carbon compared to the parent – while sustaining growth.

“This key milestone in our advanced biofuels program confirms our belief that algae can be incredibly productive as a renewable energy source with a corresponding positive contribution to our environment,” said Vijay Swarup, vice president for research and development at ExxonMobil Research and Engineering Company. “Our work with Synthetic Genomics continues to be an important part of our broader research into lower-emission technologies to reduce the risk of climate change.”

“The major inputs for phototropic algae production are sunlight and carbon dioxide, two resources that are abundant, sustainable and free,” said Oliver Fetzer, Ph.D., chief executive officer at Synthetic Genomics. “Discoveries made through our partnership with ExxonMobil demonstrate how advanced cell engineering capabilities at Synthetic Genomics can unlock biology to optimize how we use these resources and create solutions for many of today’s sustainability challenges – from renewable energy to nutrition and human health.”

Algae has been regarded as a potential sustainable fuel option, but researchers have been hindered for the past decade in developing a strain that is high in oil content and grows quickly – two critical characteristics for scalable and cost-efficient oil production. Slower growth has been an adverse effect of previous attempts to increase algae oil production volume.

A key objective of the ExxonMobil-Synthetic Genomics collaboration has been to increase the lipid content of algae while decreasing the starch and protein components without inhibiting the algae’s growth. Limiting availability of nutrients such as nitrogen is one way to increase oil production in algae, but it can also dramatically inhibit or even stop photosynthesis, stunting algae growth and ultimately the volume of oil produced.

The ability to sustain growth while increasing oil content is an important advance. Algae has other advantages over traditional biofuels because it can grow in salt water and thrive in harsh environmental conditions, therefore limiting stress on food and fresh water supplies.

Oil from algae can also potentially be processed in conventional refineries, producing fuels no different from convenient, energy-dense diesel. Oil produced from algae also holds promise as a potential feedstock for chemical manufacturing.

“The SGI-ExxonMobil science teams have made significant advances over the last several years in efforts to optimize lipid production in algae. This important publication today is evidence of this work, and we remain convinced that synthetic biology holds crucial answers to unlocking the potential of algae as a renewable energy source,” said J. Craig Venter, Ph.D., Synthetic Genomics co-founder and chairman. “We look forward to continued work with ExxonMobil so that eventually we will indeed have a viable alternative energy source.”

Since 2009, ExxonMobil and Synthetic Genomics have been partners in researching and developing oil from algae to be used as a renewable, lower-emission alternative to traditional transportation fuels. Swarup said that while the breakthrough is an important step, the technology is still many years from potentially reaching the commercial market.

“Advancements as potentially important as this require significant time and effort, as is the case with any research and development project,” Swarup said. “Each phase of our algae research, or any other similar project in the area of advanced biofuels, requires testing and analysis to confirm that we’re proceeding down a path toward scale and commercial viability.”

ExxonMobil is engaged in a wide range of research on advanced biofuels, partnering with universities, government laboratories, and other companies. Global demand for transportation-related energy is projected to increase by about 25 percent through 2040, and accelerating the reduction in emissions from the transportation sector will play a critical role in reducing global greenhouse gas emissions.

ExxonMobil is also actively researching other emission-reducing technologies, including carbon capture and sequestration. In 2016, ExxonMobil announced its partnership with Connecticut-based FuelCell Energy, Inc. to advance the use of carbonate fuel cells to economically capture carbon emissions from power plants while generating hydrogen and additional electricity. Since 2000, ExxonMobil has spent about $8 billion to develop and deploy lower-emission energy solutions across its operations.

# # #

NOTE TO EDITORS:

Vijay Swarup, Craig Venter and Oliver Fetzer will discuss the research breakthrough and answer questions during a media briefing scheduled for 10 a.m. PDT today at the San Diego Convention Center, located at 111 W. Harbor Drive, in Room 32B on the upper level. The live briefing and replay may also be accessed online via an interactive webcast.

About ExxonMobil

ExxonMobil, the largest publicly traded international energy company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products and its chemical company is one of the largest in the world. For more information, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.

Cautionary Statement: Statements of future events or conditions in this release are forward-looking statements. Actual future results, including the timing, results and impact of new technologies, could differ significantly depending on the outcome of further research and testing; the development and competitiveness of alternative technologies; the ability to develop and scale pilot projects on a cost-effective basis; political and regulatory developments; and other factors discussed in this release and under the heading “Factors Affecting Future Results” on the Investors page of ExxonMobil’s website at exxonmobil.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in health care, energy, and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at www.syntheticgenomics.com.

Contact:

ExxonMobil Media Relations, 972-444-1107
Synthetic Genomics Media Relations, 619-849-6005

Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis’ Clinical Trials

Customized suite to support Phase 1 study of Advaxis’ personalized cancer immunotherapy

SAN DIEGO, June 1, 2017 — Synthetic Genomics, Inc. and Advaxis, Inc. (NASDAQ:ADXS) announced today that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite has been designed to meet cGMP Phase 1 clinical quality and manufacturing requirements mandated by the FDA. The suite will be used to develop synthetic DNA constructs for Advaxis’ upcoming Phase 1 clinical trial of ADXS-NEO, a personalized, neoantigen-targeted cancer immunotherapy. At the core of the suite is the BioXp™ 3200 System, the world’s first benchtop automated genomic workstation that customers can purchase in an expandable fashion, combined with proprietary Synthetic Genomics genome synthesis tools to manufacture precision DNA constructs. The facility is based at SGI-DNA, a subsidiary of Synthetic Genomics.

“This cGMP suite marks the first application of Synthetic Genomics’ automated DNA synthesis directed to improve patient care, and is a significant step towards moving synthetic biology from the benchtop to the bedside,” said Oliver Fetzer, Ph.D., CEO of Synthetic Genomics. “The BioXp™ System and this first-of-its-kind cGMP suite opens the door to precision medicine, particularly when paired with the innovative technology Advaxis has developed for directing immune response towards cancer specific epitopes.”

Advaxis’ ADXS-NEO is a customized cancer treatment to stimulate an immune response against unique mutations contained in each individual patient’s tumor. It begins with identifying neoepitopes – non-synonymous mutations between a patient’s healthy cells and tumor cells. Using exome sequencing, a mutational map of the tumor is developed to select a set of neoepitopes most likely to trigger an immune response targeted at the cancer.

Under strict cGMP process controls, Synthetic Genomics rapidly converts the genetic sequences of these tumor-specific epitopes into synthetic DNA to create plasmid DNA targeting an individual patient’s cancer. Advaxis then combines the plasmid DNA with its proprietary delivery system to generate large quantities of protein containing neoepitopes that are taken up by a patient’s antigen presenting cells to activate a tumor specific T-cell response.

Daniel O’Connor, president and CEO of Advaxis, said, “Synthetic Genomics pioneered a synthetic DNA manufacturing process which has dramatically reduced turnaround time, from several months to just a few weeks. This process makes tailored immunotherapy feasible for critically-ill cancer patients who don’t have time to wait. We have been impressed by the preclinical proof of concept work completed with Synthetic Genomics, and look forward to moving ADXS-NEO into human clinical trials.”

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient’s immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient’s tumor, with plans to commence a Phase 1 clinical trial in 2017.

To learn more about Advaxis, visit www.advaxis.com and connect on TwitterLinkedInFacebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking statements.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines such as Vmax™ a novel, fast growing host system for molecular biology. To further enable synthetic biology workflows, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double stranded DNA fragments, automated cloning, as well as Next Generation Sequencing DNA library preparation. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology. More information is available at www.sgidna.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in energy, health care and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at www.syntheticgenomics.com.

Contacts:

Corporate Communications and Media
Jason Spark, Canale Communications
jason@canalecomm.com
619-849-6005

Digital-to-Biological Converter for On-Demand Production of Biologics Developed by Synthetic Genomics, Inc.

The first fully automated machine to convert digital code into functional biologics without human intervention creates entirely new avenues for precision medicine

SAN DIEGO, May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds on-demand without any human intervention. The DBC integrates many of the synthetic biology tools developed by Synthetic Genomics for creating high fidelity and complex synthetic DNA all in one fully automated unit.

The paper describing this work is the first peer-reviewed publication of its kind and was published online today in Nature Biotechnology by lead authors Kent S. Boles and Krishna Kannan, and senior authors J. Craig Venter and Daniel G. Gibson.

To demonstrate feasibility, researchers digitally transmitted a file with DNA sequence information to the DBC. The DBC converted that digital sequence into oligonucleotides, and utilized synthetic biology tools developed by Synthetic Genomics such as gene synthesis, error correction, and Gibson Assembly™ methods to create large and complex DNA constructs with high fidelity. Utilizing this DNA as a template, the DBC further produced a series of biological materials without any human intervention, such as RNA, proteins, and viral particles.

“The concept of a DBC presents a new paradigm for the manufacturing of biological materials all starting from transmitted DNA sequences,” said Daniel Gibson, Ph.D., vice president of DNA technology at Synthetic Genomics and senior author of the study. “It is easy to imagine numerous high value applications for rapid on-demand production of biological materials in healthcare, such as creating truly personalized therapeutics at a patient’s bedside and rapidly generating custom vaccines to counter an infectious disease outbreak.”

Biological products created on the DBC included DNA templates for an influenza vaccine, an RNA-based vaccine, antibody polypeptides, and a bacteriophage. The antibody polypeptides synthesized by the DBC included abatacept, ranibizumab, and trastuzumab. Biologics were created in under 2 days, which is several weeks faster than traditional biological manufacturing processes that require extended timelines and external vendors.

“The DBC is the first machine that can receive via the Internet or radio wave, digital biology in the form of DNA sequence enabling reconstitution of components of living systems,” said J. Craig Venter, Ph.D., co-founder, chairman, co-chief scientific officer of Synthetic Genomics. “We are excited by the commercial prospects of this revolutionary tool as we believe the DBC represents a major leap forward in advancing new vaccines and biologics.”

The DBC contains several components in common with the BioXp™ 3200, the world’s first instrument for printing and cloning double stranded DNA. Capabilities on the DBC that are not yet available as integrated components on the BioXp include the conversion of digital code to DNA oligonucleotides using more basic chemical inputs, and the synthesis of proteins from DNA constructs. The BioXp™ 3200 is currently available through Synthetic Genomics’ subsidiary, SGI-DNA, to improve the workflow for applications such as molecular cloning, protein production, antibody library generation, and cell engineering.

Synthetic Genomics is continuing to develop the DBC platform for several commercial applications. Continued modifications include implementing new methods for more reliable production of large, error-free, synthetic DNA and reducing dimensions of the instrument to make it more robust and portable.

The other authors on this paper that have been integral to this work include John Gill, Martina Felderman, Heather Gouvis, Bolyn Hubby, and Kurt I. Kamrud.

The paper is available on the Nature Biotechnology website at http://dx.doi.org/10.1038/nbt.3859.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines such as Vmax™ a novel, fast growing host system for molecular biology. To further enable synthetic biology workflows, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double stranded DNA fragments, automated cloning, Next Generation Sequencing DNA library preparation and cGMP manufacturing of synthetic DNA for clinical trials. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology. More information is available at www.sgidna.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in energy, health care and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at www.syntheticgenomics.com.

Contacts:
Corporate Communications and Media
Jason Spark, Canale Communications
jason@canalecomm.com
619-849-6005

Synthetic Genomics and ExxonMobil Renew Algae Biofuels Research Agreement

LA JOLLA, Calif.Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production.

ExxonMobil and Synthetic Genomics have been jointly researching and developing oil from algae for use as a renewable, lower-emission alternative to traditional transportation fuels since launching the program in 2009. Work continues toward developing strains of algae that demonstrate significantly improved photosynthetic efficiency and oil production through selection and genetic engineering of higher-performance algae strains. The agreement continues to focus on Synthetic Genomics’ core strengths in synthetic biology and builds on recent discoveries of biological pathways regulating lipid production and growth in advanced algal strains.

“Together with ExxonMobil, we have made significant strides to identify and enhance algal strains capable of high oil production while still maintaining desirable rates of growth,” said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. “The extension of our agreement reflects the tremendous progress made to date, and the promise in using our core synthetic biology technologies to build cell production systems capable of reshaping industries.”

Vijay Swarup, vice president for research and development at ExxonMobil Research and Engineering Company, said that renewal of the agreement underscores the importance of the research and recognition of milestones the team has achieved together over the past few years.

“Synthetic Genomics and ExxonMobil remain committed to advancing the scientific fundamentals of algal biofuels,” Swarup said. “We know this will be a long-term endeavor and are optimistic based on the results we have seen to date.”

The development of algae biofuels and a path toward commercial-scale production remain key components of ExxonMobil’s suite of research projects focused on producing energy to meet global demand while reducing greenhouse gas emissions to mitigate the risk of climate change.

ExxonMobil is engaged in a broad range of research on advanced biofuels, partnering with universities and other companies. The purpose of these research and development programs is to explore new technologies and seek the best pathways toward scalable and cost-effective production of advanced biofuels.

Global demand for transportation fuels is projected to rise by nearly 30 percent through 2040, and accelerating the reduction in emissions from the transportation sector will play a critical role in reducing global greenhouse gas emissions.

Cautionary Statement: Statements of future events or conditions in this release are forward-looking statements. Actual future results, including project plans and timing and the impact of new technologies, could vary depending on the outcome of further research and testing; the development and competitiveness of alternative technologies; the ability to scale pilot projects on a cost-effective basis; political and regulatory developments; and other factors discussed in this release and under the heading “Factors Affecting Future Results” on the Investors page of ExxonMobil’s website at exxonmobil.com.

About ExxonMobil
ExxonMobil, the largest publicly traded international energy company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is among the largest refiners and marketers of petroleum products and its chemical company is one of the largest in the world. For more information, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.

About Synthetic Genomics

Synthetic Genomics Inc. is a leader in the field of synthetic biology, advancing genomics to better life. Synthetic Genomics applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. Synthetic Genomics’ core technology enables two connected genome-writing businesses: engineering advantaged cell platforms and printing biological components. The company’s subsidiary, SGI-DNA, is revolutionizing science and medicine by automating next-generation genomic solutions for life sciences. Synthetic Genomics applies its integrated synthetic biology and engineering capabilities to create and commercialize novel solutions and transform existing products. Synthetic Genomics is reinventing bio-based production by improving existing production systems and developing novel, optimized production hosts. The company develops its products and solutions, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, biotherapeutics and transplantable organs. More information is available at www.syntheticgenomics.com

Contacts:
Synthetic Genomics
Corporate Communications and Media
Jason Spark, Canale Communications
jason@canalecomm.com
619-849-6005

ExxonMobil Media Relations, 972-444-1107

Synthetic Genomics Launches Vmax™ Express, a Next-Generation Protein Expression Platform for the Biotech Industry

SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble recombinant proteins faster and more efficiently than E. coli-based systems. Read more

Synthetic Genomics Announces Collaboration with Johnson & Johnson Innovation to Develop Novel Therapeutics Using Synthetic Genomics’ Replicon RNA Technology


SAN DIEGO, Jan. 5, 2017
– Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases. The deal was facilitated by Johnson & Johnson Innovation.

Leveraging its scientific leadership in writing genomes that improve upon or repurpose natural systems, Synthetic Genomics has developed a replicon RNA technology that enables a tunable, multigenic approach to elicit desired antigen expression and immune response for a variety of applications. Synthetic Genomics believes that this technology will enable the development of RNA-based therapies and vaccines that enhance and fine tune immune response against infectious diseases and cancer.
“Our replicon RNA platform is designed to enable controlled expression of antigens and therapeutic proteins to elicit effective immune response against diseases that have historically been difficult to treat or prevent,” said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. “Our expertise in programming viral systems to improve upon natural biological processes is uniquely suited to the aspirations of this collaboration with Janssen.”

About Synthetic Genomics
Synthetic Genomics, Inc., located in La Jolla, California, is a leader in the field of synthetic biology, advancing genomics to better life. Synthetic Genomics applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. Synthetic Genomics’ core technology enables two connected genome writing businesses: engineering advantaged cell platforms and printing biological components. The company’s subsidiary, SGI-DNA, is revolutionizing science and medicine by automating next-generation genomic solutions for life sciences, including the world’s first DNA printer. Synthetic Genomics applies its integrated synthetic biology and engineering capabilities to create and commercialize novel solutions and transform existing products. Synthetic Genomics is reinventing bio-based production by improving existing production systems and developing novel, optimized production hosts. The company develops its products and solutions, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, biotherapeutics and transplantable organs. More information is available at www.syntheticgenomics.com.


Corporate Communications Contact

Jason Spark
Canale Communications for Synthetic Genomics, Inc.
jason@canalecomm.com
619-849-6005